Q1 2027 Entero Healthcare Solutions Ltd Earnings Call Transcript
Key Points
- Consolidated revenue grew 38.2% YoY to INR1,940 crores, with like-for-like growth at 40% YoY, significantly outpacing the pharmaceutical market growth of 13.8%.
- EBITDA margin reached 5% in Q1 FY27, achieving the full-year guidance in the first quarter, with EBITDA growing 94% YoY.
- Gross margin expanded 147 basis points YoY to 11.4%, driven by scale-led procurement economies, a growing MedTech share, and exit from low-margin accounts.
- Return ratios improved significantly: ROSI nearly doubled YoY to 21.1% and ROE increased from 9% to 20.4%, reflecting enhanced capital efficiency.
- Net working capital days improved to 61 days from 66 days a year ago, continuing structural efficiency gains.
- MedTech revenue is on track to cross INR1,000 crores in FY27 on an organic basis, with higher margins and a full commercial role, supporting the margin story.
- The company maintains a strong two-way network effect with over 72,000 retail customers, 2,300 hospital customers, and 3,000 manufacturers, creating a difficult-to-replicate moat.
- Management reaffirmed FY27 guidance of ~23% revenue growth and 5% EBITDA margin, with confidence in sustaining and potentially improving margins.
- The company has a clear strategy to consolidate and integrate past acquisitions, focusing on organic growth and operational leverage, with potential for further margin expansion.
- Minority interest in subsidiaries is contractually defined with call options, and the company retains full operational and cash flow control, ensuring no value leakage.
- Inorganic growth of 20.4% came entirely from calendarization of prior acquisitions, with no new acquisitions in Q1 FY27, and management indicated no major acquisitions are planned for the year.
- The company is consciously exiting low-margin businesses, which impacted reported growth by around 2.5% during the quarter.
- Interest costs increased due to full-quarter impact of debt taken for the last acquisition, and are expected to remain at similar levels for the rest of the year.
- There is uncertainty regarding the sustainability of the improved IPM growth rate, as management could not isolate specific factors driving the higher industry growth.
- The company's growth is heavily reliant on increasing wallet share from existing customers, which may face limits as new customer additions are modest.
- Minority interest in subsidiaries remains a drag on attributable profit, with INR14 crores in Q1 FY27, and buyouts are subject to defined timelines (2-5 years) and conditions.
- The company did not provide quarterly balance sheet details, including gross/net debt and operating cash flow, which may limit transparency for investors.
- Management refrained from updating FY27 guidance despite strong Q1 performance, citing the need to wait for Q2 results, which may create uncertainty.
- The company's focus on organic growth may limit near-term market share gains in a fragmented market where consolidation opportunities are abundant.
- The MedTech segment, while promising, is still a smaller part of the business, and its growth is dependent on deepening existing relationships rather than new acquisitions.
Ladies and Gentlemen, Good day and welcome to the Q1 FY27 Earnings Conference Call of Entero Healthcare Solutions Limited, hosted by Monad Network Capital Limited.
As a reminder, all participant lines will be in a listen-only mode, and there will be an opportunity for you to ask questions after the presentation continues. (Operator Instructions) Please note that this conference has been recorded.
Please note this conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations the company has on the date of this call. These statements are not the guaranteed of future performance and involved risks and uncertainties that are difficult to predict. I now hand the conference over to Mr. Rahul Dani for Monarch NetWorth Capital Limited.
Thank you and over to you sir.
Yeah, thank you, Julius. Good afternoon, everyone, and a warm welcome to Entero Healthcare Solutions Q1 F5 27 call.
On the call today, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
